Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293936 · ClinicalTrials.gov registry record · NA
Post-Filter Hematocrit
A NA study of Renal Failure and Continuous Renal Replacement Therapy, sponsored by Gwyndolyn M. Radford.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07293936 is a NA study of Renal Failure and Continuous Renal Replacement Therapy that is actively recruiting participants, run by Gwyndolyn M. Radford. The registered enrollment target is 20 participants, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07293936, a NA study of Renal Failure and Continuous Renal Replacement Therapy, is actively recruiting participants, sponsored by Gwyndolyn M. Radford.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\<20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking. HCTpost=HCTpre/(FF(HCTpre-1)+1) In our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies. The procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the "measured post-filter hematocrit" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.
Conditions Studied
Interventions
- OTHER Calculated Post-Filter Hematocrit
- OTHER Measured Post-Filter Hematocrit
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-15 |
| Est. Completion | 2026-03-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293936
The ClinicalTrials.gov registry entry for NCT07293936 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower). The listed sponsor is Gwyndolyn M. Radford, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Renal Failure appearing as the primary indexed condition, and to 2 interventions - of which Calculated Post-Filter Hematocrit is the first listed.
NCT07293936 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT07293936 about?
NCT07293936 is a clinical study titled "Post-Filter Hematocrit". Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the...
What is the current status of trial NCT07293936?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-03-15. Estimated completion is 2026-03-15.
What conditions does trial NCT07293936 study?
This clinical trial studies the following conditions: Renal Failure, Continuous Renal Replacement Therapy, Hemofilter Clotting.
What interventions are being tested in trial NCT07293936?
The interventions under investigation include: Calculated Post-Filter Hematocrit (OTHER), Measured Post-Filter Hematocrit (OTHER).
Who is sponsoring clinical trial NCT07293936?
This trial is sponsored by Gwyndolyn M. Radford, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07293936 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure
COMPLETED · NA
-
Improving Patient Prioritization During Hospital-homecare Transition
COMPLETED · NA
-
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
RECRUITING · Early Phase 1
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.